As 2024 comes to a close, we packed our 500+ team into the historic Fox Theatre in Redwood City for an unforgettable-year end event! The event was an inspiring reflection on our journey this year—from groundbreaking advancements in cancer research to hearing first-hand stories from physicians and patients living with RAS-addicted cancers. It was a powerful reminder of the profound purpose behind our work. Here's to an even more impactful 2025!
Revolution Medicines
Biotechnology Research
Redwood City, California 18,055 followers
Translating Frontier Oncology Targets to Outsmart Cancer
About us
We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.
- Website
-
http://www.revmed.com
External link for Revolution Medicines
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Redwood City, California
- Type
- Public Company
- Founded
- 2014
Locations
-
Primary
700 Saginaw Dr.,
Redwood City, California 94063, US
Employees at Revolution Medicines
Updates
-
We’re excited to announce the launch of ExpectRAS.com, to help improve awareness on the prevalence of RAS in patients with pancreatic ductal adenocarcinoma (PDAC) RAS mutations are the one of the most common mutations. In fact, RAS mutations drive 90% of all PDAC cases. Revolution Medicines is committed to deepening our understanding of the role of RAS and identifying therapeutic options for patients living with pancreatic cancer. Learn more at ExpectRAS.com #Oncology #PancreaticCancer
-
This morning, we hosted an investor webcast where we provided clinical updates from our RAS(ON) inhibitor portfolio. You can read more about today's event in our press release (https://lnkd.in/gRtgsAZW) and access the webcast recording on the "Events and Presentations" page of our website.
-
Next Monday, December 2nd at 8:00am ET, Revolution Medicines will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio. To learn more about the event, read today’s announcement. https://lnkd.in/gxcRZasR
-
Thanksgiving is a time to reflect on what we’re grateful for. At Revolution Medicines, our team tops the list! This week, we gathered to celebrate the season together, sharing stories, food, and gratitude for each team member’s dedication to advancing breakthroughs in cancer research. Moments like these remind us of the power of collaboration, innovation, and community. Here’s to a season of gratitude and the inspiring work we continue to do together. Happy Thanksgiving from all of us at Revolution Medicines!
-
November is #LungCancerAwarenessMonth. Lung cancer is the leading cause of cancer deaths in the U.S. Our research is aimed at developing innovative therapies for RAS-addicted cancers, including lung cancer. This month, we stand with all those impacted by lung cancer and remain committed to help drive progress as we combat this disease.
-
RevMed is #hiring! We’re seeking highly motivated, experienced Medical Science Liaisons to join our diverse team of individuals who are united in our singular pursuit – to make a difference in the lives of patients living with RAS-addicted cancers. Our mission drives our work every day. Learn more about life at RevMed and check out our current openings! https://lnkd.in/gYzdntMF #BeARevolutionary #HealthcareJobs #HiringNow
-
This Pancreatic Cancer Awareness Month, we’re honored to welcome the Pancreatic Cancer Action Network to our campus to help increase awareness about this challenging cancer. The resilience of patients – and their loved ones – inspires our team to advance breakthrough therapies and help improve patient outcomes. At Revolution Medicines, we are committed to developing novel targeted therapies for RAS-addicted cancers like pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. Thank you PanCan for the visit! #PancreaticCancerAwareness #PanCANawareness
-
Today we announced Q3 earnings and recent business highlights. Read the full announcement here: https://lnkd.in/ge22fVzh
-
Congratulations to our Senior Vice President of Medical Affairs, Mary Pinder-Schenck, MD for being named to PharmaVoice's 100 list in the life-sciences space! Mary's expertise in oncology patient care, clinical research, and medical affairs is instrumental in our pursuit to deliver innovative, targeted medicines for patients living with cancer. Join us in celebrating Mary's dedication to science and the remarkable recognition of her work. We're excited to see what the future holds under her visionary leadership! https://lnkd.in/e9pFrenZ #PV100 #LifeSciences #Pharma #PharmaVoice100 #PharmaLead